While the biologics group had significantly lower serum levels of β-D-glucan (100 versus 231 pg/mL, P = 0.039) and CRP (5.2 versus 10.6 mg/dL, P = 0.039) than the nonbiologics group, the biologics group had significantly higher lymphocyte counts than the nonbiologics group (1429 versus 585 cells/μL, P = 0.033), implying that patients on biologics develop PCP with almost normal lymphocyte counts accompanied with low β-D-glucan levels. The gene discussed is PPIB; the disease is pneumocystosis.